Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
Public ClinicalTrials.gov record NCT01877694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.
Study identification
- NCT ID
- NCT01877694
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 217 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2013
- Primary completion
- Nov 30, 2014
- Completion
- Dec 31, 2014
- Last update posted
- May 27, 2015
2013 – 2015
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35244 | — |
| Not listed | Phoenix | Arizona | 85032 | — |
| Not listed | Anaheim | California | 92804 | — |
| Not listed | Bellflower | California | 90706 | — |
| Not listed | Glendale | California | 91204 | — |
| Not listed | Huntington Beach | California | 92647 | — |
| Not listed | Clearwater | Florida | 33761 | — |
| Not listed | Woodstock | Georgia | 30189 | — |
| Not listed | Evansville | Indiana | 47714 | — |
| Not listed | Newton | Kansas | 67114 | — |
| Not listed | Whitehouse Station | New Jersey | 08889 | — |
| Not listed | Huntersville | North Carolina | 28078 | — |
| Not listed | Winston-Salem | North Carolina | 27101 | — |
| Not listed | Cincinnati | Ohio | 45246 | — |
| Not listed | Dayton | Ohio | 45432 | — |
| Not listed | Corsicana | Texas | 75110 | — |
| Not listed | San Antonio | Texas | 78215 | — |
| Not listed | Clinton | Utah | 84015 | — |
| Not listed | Charlottesville | Virginia | 22902 | — |
| Not listed | Midlothian | Virginia | 23113 | — |
| Not listed | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01877694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2015 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01877694 live on ClinicalTrials.gov.